EUCTR2008-000036-41-GB进行中（未招募）1 期
An antimicrobial cream for the treatment of impetigo - IPTG-01: A new skin cream for impetigo
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 242
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •i. Male or female patients aged 18 months and over.
- •ii. Diagnosis of uncomplicated, localised, primary non-bullous (crusted) impetigo considered, by the Investigator, suitable for treatment with topical antibacterial therapy only.
- •iii. Patients presenting with at least 1, but no more than 10, discrete impetigo lesions.
- •iv. Patients with a total surface area of impetigo involvement not exceeding 100 cm2 (in the case of patients aged 18 years and above) or not exceeding 2% of the total body surface area (in case of patients younger than 18 years).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 162
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •i) Patients with a history of intolerance or skin sensitivity to any of the ingredients.
- •ii) Patients with underlying skin disease or trauma with clinical evidence of secondary infection, or a bacterial skin infection that, in the Investigator’s opinion, is not suitable for treatment with topical antibacterial therapy only (e.g. diabetic foot infections, extensive cellulitis, furunculosis, or abscess).
- •iii) Patients with signs and symptoms of systemic infection (e.g. fever with oral temperature above 38.3ºC).
- •iv) Patients who have applied any topical therapeutic agent (including corticosteroids, antibacterials and antifungals) directly to the impetigo lesion(s) within 48 hours prior to study entry.
- •v) Patients who have taken any systemic antibacterial or steroid/corticosteroid treatment within 48 hours prior to study entry.
- •vi) Patients with systemic diseases which, in the opinion of the Investigator, may adversely influence their participation in the trial.
- •vii) Patients who have received any unlicensed drug within the last 30 days or who are scheduled to receive an investigative drug other than the study medication during the period of the study.
- •viii) Patients who are immunocompromised.
- •ix) Female patients who are pregnant or lactating (although there are no particular safety concerns in these patient groups, it is generally inappropriate for them to participate in clinical trials without overriding justification. Negative pregnancy testing will not be necessary, and there are no safety concerns, as such, about female patients potentially conceiving while taking part in the study).
- •x) Patients considered unable or unlikely to attend the necessary follow-up visits at day 8 (or day 9 or 10) and potentially day 15 (or day 16 or 17), which are not part of the standard clinical care.
- •xi) Patients who, in the opinion of the Investigator, have impetigo lesions which may require being covered with gauze, bandages and/or nappies during treatment with the IMP.
- •xii) Patients with another member of the household participating in the study during the same treatment period (this is to avoid possible mix up between assigned treatments).
- •xiii) Employees of the Sponsor or the Investigators, or their immediate family members (partner, offspring, parents, siblings or sibling’s offspring).
研究者
相似试验
已完成
不适用
Topical mupirocin or gentamicin cream at the exit site for prevention of peritoneal dialysis catheter-related infections and withdrawal from peritoneal dialysis.End-stage renal diseaseJPRN-UMIN000034437The Japanese Society of dialysis and therapy100
已完成
不适用
The use of topical antibacterial skin ointment (TASO) in the management of soft tissue wounds: A randomised controlled trialInjury, Occupational Diseases, Poisoning: Wound healingInjury, Occupational Diseases, PoisoningWound healingISRCTN39666702Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
尚未招募
1 期
Skin cleansing soap with Candida auris: clinical trial to evaluate safety and efficacyCutaneous CandidiasisC01.150.703.160RBR-10xv7t6bCentro de Ciências Médicas da Universidade Federal de Pernambuco
已完成
不适用
Topical application of novel anti-microbial peptide, AG30/5C, for cutaneous ulcersCutaneous ulcersJPRN-UMIN000010268Medical Center for Translational Research, Osaka University Hospital6
已完成
不适用
Topical 5% Imiquimod cream for vulvar Paget's disease: clinical efficacy, safety and immunological responseNL-OMON42251Radboud Universitair Medisch Centrum25